Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Sanofi SA — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.53, while Sanofi SA trades at $44.19 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| FEPI | SNY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $52.34 |
52-Week Low | $38.13 | $41.33 |
Market Cap | — | $103.94B |
Enterprise Value | — | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
